Y-mAbs Therapeutics, Inc. (YMAB)

15.12 +0.12 (+0.80%) As of 01:29PM EDT. Market open.

Y-mAbs Therapeutics, Inc.

230 Park Avenue
Suite 3350
New York, NY 10169
United States
646 885 8505
https://www.ymabs.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 100

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thomas Gad	Founder, Chief Business Officer & Vice Chairman	1.05M	N/A	1971
Mr. Bo Kruse	Executive VP, Secretary, Treasurer & CFO	685.02k	N/A	1973
Ms. Susan Smith	Senior VP & Chief Commercial Officer	710k	N/A	1971
Mr. Michael Rossi	CEO, President & Director	N/A	N/A	1971
Mr. Joris Wiel Jan Wilms	Senior VP & COO	N/A	N/A	1974
Dr. Torben Lund-Hansen M.Sc., Ph.D.	Senior VP & CTO	N/A	N/A	1951

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Corporate governance

Y-mAbs Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 4; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.